Inovio Demonstrates 80% 6-Month Progression-Free Survival In Phase 2 Glioblastoma Multiforme (GBM) Study with INO-5401 In Combination with PD-1 Inhibitor Libtayo® (cemiplimab)

Stock Information for Inovio Pharmaceuticals Inc.

Loading

Please wait while we load your information from QuoteMedia.